Evidence map›Paper›PMID 32776832›Full record

Trial reportRadiology2021

Diagnostic Performance of Chest CT for SARS-CoV-2 Infection in Individuals with or without COVID-19 Symptoms.

Kristof De Smet, Dieter De Smet, Thomas Ryckaert, Emanuel Laridon, Birgit Heremans, Ruben Vandenbulcke, Ingel Demedts, Bernard Bouckaert, Stefaan Gryspeerdt, Geert A Martens

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 2 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. The current state of forensic imaging - post mortem imaging.International journal of legal medicine · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Imaging strategies used in emergency departments for the diagnostic workup of COVID-19 patients during the first wave of the pandemic: a cost-effectiveness analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kristof De Smet *From the Department of Radiology (K.D.S., T.R., E.L., B.H., R.V., S.G.), Department of Laboratory Medicine (D.D.S., G.A.M.), and Department of Pulmonary Diseases (I.D., B.B.), AZ Delta General Hospital, Deltalaan 1, 8800 Roeselare, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium (G.A.M.); and Department of Pathology, Molecular and Cellular Medicine, Brussels Free University, Brussels, Belgium (G.A.M.).ORCID 0000-0003-0784-9325
Dieter De Smet *From the Department of Radiology (K.D.S., T.R., E.L., B.H., R.V., S.G.), Department of Laboratory Medicine (D.D.S., G.A.M.), and Department of Pulmonary Diseases (I.D., B.B.), AZ Delta General Hospital, Deltalaan 1, 8800 Roeselare, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium (G.A.M.); and Department of Pathology, Molecular and Cellular Medicine, Brussels Free University, Brussels, Belgium (G.A.M.).ORCID 0000-0001-8810-5808
Thomas RyckaertFrom the Department of Radiology (K.D.S., T.R., E.L., B.H., R.V., S.G.), Department of Laboratory Medicine (D.D.S., G.A.M.), and Department of Pulmonary Diseases (I.D., B.B.), AZ Delta General Hospital, Deltalaan 1, 8800 Roeselare, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium (G.A.M.); and Department of Pathology, Molecular and Cellular Medicine, Brussels Free University, Brussels, Belgium (G.A.M.).
Emanuel LaridonFrom the Department of Radiology (K.D.S., T.R., E.L., B.H., R.V., S.G.), Department of Laboratory Medicine (D.D.S., G.A.M.), and Department of Pulmonary Diseases (I.D., B.B.), AZ Delta General Hospital, Deltalaan 1, 8800 Roeselare, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium (G.A.M.); and Department of Pathology, Molecular and Cellular Medicine, Brussels Free University, Brussels, Belgium (G.A.M.).
Birgit HeremansFrom the Department of Radiology (K.D.S., T.R., E.L., B.H., R.V., S.G.), Department of Laboratory Medicine (D.D.S., G.A.M.), and Department of Pulmonary Diseases (I.D., B.B.), AZ Delta General Hospital, Deltalaan 1, 8800 Roeselare, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium (G.A.M.); and Department of Pathology, Molecular and Cellular Medicine, Brussels Free University, Brussels, Belgium (G.A.M.).ORCID 0000-0002-9411-4126
Ruben VandenbulckeFrom the Department of Radiology (K.D.S., T.R., E.L., B.H., R.V., S.G.), Department of Laboratory Medicine (D.D.S., G.A.M.), and Department of Pulmonary Diseases (I.D., B.B.), AZ Delta General Hospital, Deltalaan 1, 8800 Roeselare, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium (G.A.M.); and Department of Pathology, Molecular and Cellular Medicine, Brussels Free University, Brussels, Belgium (G.A.M.).ORCID 0000-0002-1022-5970
Ingel DemedtsFrom the Department of Radiology (K.D.S., T.R., E.L., B.H., R.V., S.G.), Department of Laboratory Medicine (D.D.S., G.A.M.), and Department of Pulmonary Diseases (I.D., B.B.), AZ Delta General Hospital, Deltalaan 1, 8800 Roeselare, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium (G.A.M.); and Department of Pathology, Molecular and Cellular Medicine, Brussels Free University, Brussels, Belgium (G.A.M.).ORCID 0000-0002-2949-8821
Bernard BouckaertFrom the Department of Radiology (K.D.S., T.R., E.L., B.H., R.V., S.G.), Department of Laboratory Medicine (D.D.S., G.A.M.), and Department of Pulmonary Diseases (I.D., B.B.), AZ Delta General Hospital, Deltalaan 1, 8800 Roeselare, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium (G.A.M.); and Department of Pathology, Molecular and Cellular Medicine, Brussels Free University, Brussels, Belgium (G.A.M.).ORCID 0000-0003-4363-1024
Stefaan GryspeerdtFrom the Department of Radiology (K.D.S., T.R., E.L., B.H., R.V., S.G.), Department of Laboratory Medicine (D.D.S., G.A.M.), and Department of Pulmonary Diseases (I.D., B.B.), AZ Delta General Hospital, Deltalaan 1, 8800 Roeselare, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium (G.A.M.); and Department of Pathology, Molecular and Cellular Medicine, Brussels Free University, Brussels, Belgium (G.A.M.).ORCID 0000-0002-4935-6476
Geert A MartensFrom the Department of Radiology (K.D.S., T.R., E.L., B.H., R.V., S.G.), Department of Laboratory Medicine (D.D.S., G.A.M.), and Department of Pulmonary Diseases (I.D., B.B.), AZ Delta General Hospital, Deltalaan 1, 8800 Roeselare, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium (G.A.M.); and Department of Pathology, Molecular and Cellular Medicine, Brussels Free University, Brussels, Belgium (G.A.M.).ORCID 0000-0003-1208-6289
Ghent University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The use of chest CT for coronavirus disease 2019 (COVID-19) diagnosis or triage in health care settings with limited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) capacity is controversial. COVID-19 Reporting and Data System (CO-RADS) categorization of the level of COVID-19 suspicion might improve diagnostic performance. Purpose To investigate the value of chest CT with CO-RADS classification to screen for asymptomatic SARS-CoV-2 infections and to determine its diagnostic performance in individuals with COVID-19 symptoms during the exponential phase of viral spread. Materials and Methods In this secondary analysis of a prospective trial, from March 2020 to April 2020, parallel SARS-CoV-2 PCR and CT with categorization of COVID-19 suspicion was performed with CO-RADS for individuals with COVID-19 symptoms and control participants without COVID-19 symptoms admitted to the hospital for medical emergencies unrelated to COVID-19. CT with CO-RADS was categorized on a five-point scale from 1 (very low suspicion) to 5 (very high suspicion). Area under the receiver operating curve (AUC) was calculated in symptomatic versus asymptomatic individuals to predict positive SARS-CoV-2 PCR, and likelihood ratios for each CO-RADS score were used for rational selection of diagnostic thresholds. Results A total of 859 individuals (median age, 70 years; interquartile range, 52-81 years; 443 men) with COVID-19 symptoms and 1138 control participants (median age, 68 years; interquartile range, 52-81 years; 588 men) were evaluated. CT with CO-RADS had good diagnostic performance (

Indexed as

Tomography, X-Ray ComputedAgedAged, 80 and overAsymptomatic InfectionsCOVID-19FemaleHumansMaleMiddle AgedProspective StudiesThorax

Identifiers

PMID32776832
PMCPMC7418927
OpenAlexW3047929474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.